• Subscribe
  • Log In
  • Corporate
  • DONATE
  • LinkedIn
  • X
The Global Health Report
  • Policy
  • Companies
  • Research
  • People
  • AI
Latest news
  • May 22, 2026 | Anthropic, Gates $200m deal to speed up drug discovery
  • May 18, 2026 | Gavi tops up African vaccine fund
  • May 15, 2026 | Rare Ebola strain kills 65 in DRC
  • May 13, 2026 | Israeli forces killing children in Palestine – UN agency
  • May 11, 2026 | Biovac gets $20 mln loan to build vaccine plant
A four-year deal between Anthropic and the Gates Foundation will combine $200 milion with access to Claude credits and technical support. Image: “Working in the DMPK Lab” by National Center for Advancing Translational Sciences, Public Domain Mark

AI May 22, 2026

Anthropic, Gates $200m deal to speed up drug discovery

Artificial intelligence firm Anthropic will make its Claude model available to drug developers to accelerate medicine development as part of a $200 million agreement with…

Read More
Gavi plans to buy up to 70 million vaccine doses from manufacturers on the continent. Image from Flickr courtesy of UKAID

Vaccines

Gavi tops up African vaccine fund

There are currently no licenced treatments for non-Zaire strains, and no vaccines. Image from CDC Global, CC BY 2.0 , via Wikimedia Commons

Disease

Rare Ebola strain kills 65 in DRC

The agency said on average at least one child had been killed every week since January 2025. Image from Flickr courtesy of The Advocacy Project

Disease

Israeli forces killing children in Palestine – UN agency

The plant will make vaccines for diseases such as polio, meningitis, pneumonia and cholera. Image Sadegh Nikgostar, CC BY 4.0 , via Wikimedia Commons

Vaccines

Biovac gets $20 mln loan to build vaccine plant

CPHIA 2026 is being organised in partnership with the Ethiopian government under the theme Africa’s Health Security and Sovereignty: Transformation from health dependency and vulnerability. Image from Flickr

Policy

Africa to hold health ownership event as aid shrinks

The OECD says countries need to collaborate better in AI technologies. Image courtesey of OECD

AI

Countries aren’t recruiting enough AI workers – OECD

Valneva has issued almost 16 million new shares. Image courtesy of Valneva

Companies

Valneva shores up balance sheet after mixed trial results

Coartem Baby was developed by Novartis with scientific and financial support from the Medicines for Malaria Venture. Image from flickr, courtesy of World Bank

Medicines

Novartis’ malaria drug for newborns cleared by WHO

Monitoring and preparing for disease outbreaks should be the top consideration for AI developers in global health, the first-ever global priority-setting report has concluded. Image Wikimedia Commons, courtesey of IICD

AI April 29, 2026

Outbreaks top AI concern – priority-setting report

Monitoring and preparing for disease outbreaks should be the top consideration for AI developers in global health, the first-ever global priority-setting report has concluded. The…

1 2 3 4 »

Most popular

  • The US has so far funded a third of the cost of fighting mpox.US aid suspension threatens mpox fight
  • Uganda has started the world’s biggest malaria vaccination campaign.Uganda launches largest-ever malaria vaccine drive
  • African countries are at risk of missing out on flu jabs in the case of a pandemic, according to the latest study from the WHO.Africa could miss out in a pandemic – study
  • The world is off track to meet the health-related SDGs, amid a darkening geopolitical outlook for health spending.World off-track to meet health SDGs – WHO
  • South Africa's Minister of Health Aaron Motsoaledi said the country plans to make Gilead’s twice-yearly HIV preventative lenacapavir into a 'public good'South Africa to make Gilead’s lenacapavir a ‘public good’
  • Privacy Policy
  • Account
  • About us

Copyright 2026 | MH Newsdesk by MH Themes

Receive our free weekly newsletter

We don’t spam! Read our privacy policy for more info.

Check your inbox or spam folder to confirm your subscription.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.